Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome (Colibri)
Primary Purpose
Down Syndrome
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Biological sampling
Sponsored by
About this trial
This is an interventional basic science trial for Down Syndrome
Eligibility Criteria
Inclusion Criteria: Twins of a heterokaryotypic monozygotic pair discordant for DS Twins of a sex- and class of age-matched dizygotic pair discordant for DS, Sex- and class of age-matched patient with mosaic T21 Subject's parents/legal representatives willing to give written informed consent. Subject and his/her parents/legal representatives must be able/willing to comply with the protocol. Subject covered by social welfare. Exclusion Criteria: None
Sites / Locations
- Institut Jérôme LejeuneRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Down syndrome children
Arm Description
Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
Outcomes
Primary Outcome Measures
Analysis of the coding and non-coding genetic variations between participants
Whole Genome Sequencing of DNA samples
Study of epigenetic modifications
DNA methylation pattern
Identification of active genes
Analysis of transcriptomic profile from RNA samples
Determination of the mechanisms of genes regulation
Analysis of transcriptomic profile from RNA samples
Definition of the network of genes expression
Analysis of transcriptomic profile from RNA samples
Identification of the proteins regulated differently
Analysis of proteomic profile from plasma samples
Link specific proteins to some specific complications seen in patients with Down syndrome
Analysis of proteomic profile from plasma samples
Secondary Outcome Measures
Full Information
NCT ID
NCT05767216
First Posted
February 7, 2023
Last Updated
March 1, 2023
Sponsor
Institut Jerome Lejeune
1. Study Identification
Unique Protocol Identification Number
NCT05767216
Brief Title
Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome
Acronym
Colibri
Official Title
Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 20, 2022 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Jerome Lejeune
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Heterokaryotypic monozygotic twins discordant for Down syndrome (DS) are very rare, with an incidence estimated to be less than 1 over 7,000,000 pregnancy in the general population. Sharing the same genetic patrimony, except for an additional chromosome 21 for one of them, any gene-expression difference between them could be attributed only to the supernumerary chromosome 21 and not to polymorphic variability in the rest of the genome. The setting up of a prospective longitudinal study will offer the major advantage of allowing genetic and epigenetic comparisons between them and to obtain important information on the impact of the environment in which they live and grow up.
Detailed Description
It is planned to perform multi-omics analyses in order to reach an integrated understanding of the effect of genomic changes on protein expression, on biochemical posttranslational modifications of the synthetized proteins and on the modulation of some signalling pathways.
This study will also allow the generation of induced Pluripotent Stem Cells (iPSCs) from blood cells and fibroblasts of the monozygotic twins useful as in-vitro models to study the pathogenesis and the pathophysiology of Down syndrome. All this may shed the light on new research approaches in Down syndrome.
At last, the human gut microbiome, referring to the total microbial population in the human gastrointestinal tract, although thought to have its own impact, will also be studied. The microbiome is known to play a crucial role mainly in protecting the host against pathogenic microbes, modulating immunity, regulating metabolic processes, and controlling neuropsychiatric behaviour
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Down Syndrome
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Down syndrome children
Arm Type
Other
Arm Description
Two pairs of twins discordant for Down syndrome and 1 children with mosaic Down syndrome will be recruited. Blood, skin and feces samples will be specifically collected for the purpose of the study.
Intervention Type
Other
Intervention Name(s)
Biological sampling
Intervention Description
Blood, skin and stool samples for laboratory analysis
Primary Outcome Measure Information:
Title
Analysis of the coding and non-coding genetic variations between participants
Description
Whole Genome Sequencing of DNA samples
Time Frame
1 year
Title
Study of epigenetic modifications
Description
DNA methylation pattern
Time Frame
1 year
Title
Identification of active genes
Description
Analysis of transcriptomic profile from RNA samples
Time Frame
1 year
Title
Determination of the mechanisms of genes regulation
Description
Analysis of transcriptomic profile from RNA samples
Time Frame
1 year
Title
Definition of the network of genes expression
Description
Analysis of transcriptomic profile from RNA samples
Time Frame
1 year
Title
Identification of the proteins regulated differently
Description
Analysis of proteomic profile from plasma samples
Time Frame
1 year
Title
Link specific proteins to some specific complications seen in patients with Down syndrome
Description
Analysis of proteomic profile from plasma samples
Time Frame
1 year
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
11 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Twins of a heterokaryotypic monozygotic pair discordant for DS
Twins of a sex- and class of age-matched dizygotic pair discordant for DS,
Sex- and class of age-matched patient with mosaic T21
Subject's parents/legal representatives willing to give written informed consent.
Subject and his/her parents/legal representatives must be able/willing to comply with the protocol.
Subject covered by social welfare.
Exclusion Criteria:
None
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sophie Durand
Phone
0033156586300
Email
sophie.durand@institutlejeune.org
Facility Information:
Facility Name
Institut Jérôme Lejeune
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie Durand
Phone
0156586300
Email
sophie.durand@institutlejeune.org
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome
We'll reach out to this number within 24 hrs